Impact Biomedical (IBO) Net Margin (2022 - 2026)

Impact Biomedical (IBO) has reported Net Margin for 3 consecutive years, with 23333.33% the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Net Margin rose 18169524.0% year-over-year to 23333.33%; the trailing twelve-month figure through Jun 2026 stood at 53745.71% (up 1376832.0% YoY), and the FY2022 full-year result was 14102.0%, changed N/A from the prior year.
• Net Margin rose to 23333.33% in Q2 2026 per IBO's latest filing, from 32628.57% in the prior quarter.
• Across five years, Net Margin topped out at 1464.0% in Q2 2022 and bottomed at 205028.57% in Q2 2025.
• Historically, Net Margin has averaged 54129.78% across 3 years, with a median of 23333.33% in 2026.
• The widest YoY moves for Net Margin: up 18169524 bps in 2026, down 18169524 bps in 2026.
• Over 3 years, Net Margin stood at 1464.0% in 2022, then plunged by 460 bps to 8194.44% in 2025, then sank by 185 bps to 23333.33% in 2026.
• According to Business Quant data, Net Margin over the past three periods registered 23333.33%, 32628.57%, and 8194.44% for Q2 2026, Q1 2026, and Q3 2025 respectively.